Mersana Therapeutics, Inc. (MRSN) financial statements (2021 and earlier)

Company profile

Business Address 840 MEMORIAL DRIVE
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments10070115
Cash and cash equivalents626027
Short-term investments371088
Receivables 01
Other undisclosed current assets242
Total current assets:10174118
Noncurrent Assets
Operating lease, right-of-use asset3
Property, plant and equipment232
Long-term investments and receivables  10
Long-term investments  10
Other noncurrent assets120
Total noncurrent assets:6413
TOTAL ASSETS:10879131
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities162310
Accounts payable7113
Accrued liabilities9127
Deferred revenue5
Debt3  
Deferred rent credit 0
Deferred revenue and credits22
Contract with customer, liability46
Other liabilities0  
Total current liabilities:246932
Noncurrent Liabilities
Long-term debt and lease obligation5  
Long-term debt, excluding current maturities4  
Operating lease, liability1
Liabilities, other than long-term debt0029
Deferred revenue and credits29
Deferred rent credit 0
Other liabilities0  
Total noncurrent liabilities:5029
Total liabilities:297061
Stockholders' equity
Stockholders' equity attributable to parent78970
Common stock000
Additional paid in capital271173168
Accumulated other comprehensive income (loss)0(0)(0)
Accumulated deficit(192)(164)(98)
Total stockholders' equity:78970
TOTAL LIABILITIES AND EQUITY:10879131

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
Gross profit:421118
Operating expenses(72)(76)(57)
Operating loss:(30)(66)(40)
Nonoperating income211
Investment income, nonoperating2  
Interest and debt expense(0)  
Loss before gain (loss) on sale of properties:(28)(64)(39)
Other undisclosed net income0  
Net loss available to common stockholders, diluted:(28)(64)(39)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
Net loss:(28)(64)(39)
Other comprehensive income (loss)00(0)
Comprehensive loss, net of tax, attributable to parent:(28)(64)(39)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: